Last week, I hosted an hourlong webinar on future directions for cancer immunotherapy. I focused my talk on three promising avenues of research: checkpoint inhibitors that target the protein called TIGIT; cell therapies utilizing NK, or natural killer, cells; and messenger RNA-based cancer vaccines.
The goal with all of these approaches is to increase the number of patients with cancer who can benefit from immunotherapy.
I tried to answer as many questions as time allowed, but I couldn’t get to them all. To make up for it, I’ve collected more of your questions and compiled responses below.
About the Author Reprints
Hi Adam,
I’m a rising oncology fellow at Northwestern Lurie Cancer Center in Chicago. I watched your immuno-oncology webinar recently and just wanted to say I thought it was outstanding. Really well done and look forward to seeing how some future milestones play out. Great presentation!